GW Pharmaceuticals Plc
(London Stock Exchange, The : GWPRF)

( )
GWPRF After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
HZNPHorizon Therapeutics Plc -2.41%55.856.5%$169.16m
CTLTCatalent, Inc. -0.72%77.452.1%$112.22m
VRXValeant Pharmaceuticals International, Inc. 1.22%17.4014.1%$102.38m
JAZZJazz Pharmaceuticals Plc -0.99%105.552.4%$76.64m
UTHRUnited Therapeutics Corp. -1.27%115.9514.3%$67.46m
BHCBausch Health Cos., Inc. 1.22%17.400.0%$65.42m
ICPTIntercept Pharmaceuticals, Inc. -4.35%43.1316.8%$62.97m
PCRXPacira Biosciences, Inc. -3.84%55.5810.3%$54.77m
AXSMAxsome Therapeutics, Inc. -7.59%76.741.9%$48.18m
ZGNXZogenix, Inc. -2.75%26.497.5%$47.25m
PRGOPerrigo Co. Plc 0.62%55.516.8%$43.49m
MYOKMyoKardia, Inc. -2.41%90.621.8%$43.21m
ARGXargenx SE 0.12%250.820.0%$42.04m
GWPHGW Pharmaceuticals Plc 3.35%132.196.2%$41.23m
ICLRICON plc 1.08%171.794.3%$37.33m

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.